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ABSTRACT: Aspartate (Asp) derivatives are privileged
compounds for investigating the roles governed by excitatory
amino acid transporters (EAATs) in glutamatergic neuro-
transmission. Here, we report the synthesis of various Asp
derivatives with (cyclo)alkyloxy and (hetero)aryloxy sub-
stituents at C-3. Their pharmacological properties were
characterized at the EAAT1−4 subtypes. The L-threo-3-
substituted Asp derivatives 13a−e and 13g−k were non-
substrate inhibitors, exhibiting pan activity at EAAT1−4 with
IC50 values ranging from 0.49 to 15 μM. Comparisons
between (DL-threo)-19a−c and (DL-erythro)-19a−c Asp
analogues conﬁrmed that the threo conﬁguration is crucial for the EAAT1−4 inhibitory activities. Analogues (3b−e) of L-
TFB-TBOA (3a) were shown to be potent EAAT1−4 inhibitors, with IC50 values ranging from 5 to 530 nM. Hybridization of
the nonselective EAAT inhibitor L-TBOA with EAAT2-selective inhibitor WAY-213613 or EAAT3-preferring inhibitor NBI-
59159 yielded compounds 8 and 9, respectively, which were nonselective EAAT inhibitors displaying considerably lower IC50
values at EAAT1−4 (11−140 nM) than those displayed by the respective parent molecules.
■ INTRODUCTION
L-Glutamate (Glu) is the major excitatory neurotransmitter in
the mammalian central nervous system (CNS), where it
mediates numerous physiological and pathophysiological
processes.1−5 However, accumulation of high levels of
extracellular Glu may lead to hyperactivity in the glutamatergic
system and neuronal injury.6 Five subtypes of excitatory amino
acid transporters (termed EAAT1−5 in humans) have been
identiﬁed in glial cells (predominantly EAAT1,2) and neurons
(predominantly EAAT3−5), where they are key players in the
regulation of glutamatergic transmission.7 EAAT2 is the major
contributor to this, as it is estimated to be responsible for over
90% of total extracellular Glu uptake in the brain, while
EAAT1 and EAAT3 are also widely expressed in the CNS.
Notably, EAAT4 and EAAT5 are almost speciﬁcally located in
cerebellum and the retina, respectively. Malfunction of EAATs
has been implicated in many neurological disorders, such as
Alzheimer’s disease, epilepsy, amyotrophic lateral sclerosis, and
Huntington’s disease.8 However, in contrast to the consid-
erable medicinal chemistry eﬀorts in the ﬁelds of ionotropic
and metabotropic Glu receptors, the EAATs have received
much less attention as putative drug targets.4
One of the most important scaﬀolds for the development of
EAAT ligands is the endogenous substrate L-aspartate (1, L-
Asp, Figure 1B). Represented by L-threo-3-benzyloxyaspartate
(2, L-TBOA, Figure 1B), 3-aryloxy substituted Asp analogues
were identiﬁed as the ﬁrst class of nontransportable EAAT
inhibitors by Shimamoto and co-workers.9−11 None of these
analogues exhibited substantial selectivity or preference toward
diﬀerent EAAT subtypes. Further development of the 3-
aryloxy substituted Asp analogues as pharmacological tools in
neurobiological research led to the identiﬁcation of (L-threo)-3-
[3-[4-(triﬂuoromethyl)benzoylamino]benzyloxy]aspartate (3a,
L-TFB-TBOA, Figure 1B), the most potent EAAT inhibitor
reported to date.12−14 Interestingly, elimination of the ether
oxygen in L-TBOA (2) yielded the analogue L-threo-3-
benzylaspartate (4, L-3-BA, Figure 1B), which displayed a
10-fold preference as an inhibitor for EAAT3 over EAAT1 and
EAAT2.15 Most recently, [3-(triﬂuoromethyl)phenyl]-
sulfonamide-L-aspartate (5, Figure 1B) was found to be a
potent EAAT2 inhibitor exhibiting over 30-fold selectivity for
EAAT2 over EAAT1 and EAAT3.16 In addition, other
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medicinal chemistry eﬀorts have focused on 4-carboxylate-
modiﬁed Asp analogues, which resulted in the discovery of N4-
[4-(2-bromo-4,5-diﬂuorophenoxy)phenyl]-L-asparagine (6,
WAY-213613) as a EAAT2-selective nonsubstrate inhibi-
tor17−19 and N4-(9H-ﬂuoren-2-yl)-L-asparagine (7, NBI-
59159) as an EAAT3-preferring inhibitor (Figure 1B).19,20
The fact that derivatization of the Asp structure has yielded
several important classes of EAAT inhibitors (Figure 1B)
encouraged us to further explore the potential of this scaﬀold
in this ﬁeld (Figure 1A). Here, we describe the chemo-
enzymatic asymmetric synthesis of a series of novel Asp
derivatives comprising (cyclo)alkyloxy and (hetero)aryloxy
substituents at the C-3 position, using an engineered variant of
methylaspartate ammonia lyase (MAL-L384A) as the bio-
catalyst.21,22 In addition, we report the synthesis of two Asp
derivatives by hybridization of the nonselective EAAT inhibitor
L-TBOA (2) with the EAAT2-selective inhibitor WAY-213613
(6) or the EAAT3-preferring inhibitor NBI-59159 (7). The
pharmacological properties of the newly synthesized Asp
derivatives, as well as those of previously synthesized analogues
and homologues of L-TFB-TBOA, have been characterized at
stable cell lines expressing the human EAAT1−3 and rat
EAAT4 and thus the structure−activity relationships of these
analogues have been elucidated.
■ RESULTS AND DISCUSSION
Chemoenzymatic Synthesis of 3-Substituted Asp
Analogues. The asymmetric synthesis of Asp derivatives
with alkyloxy or aryloxy substituents at the C-3 position has
proven to be challenging. Shimamoto and co-workers ﬁrst
reported the synthesis of L-TBOA (2) through an elaborate 11-
step procedure.11 A rapid chemoenzymatic methodology for
asymmetric synthesis of 2 and its analogues by using MAL-
L384A as biocatalyst has been developed in our group.21,22 To
further explore the substrate scope and synthetic usefulness of
MAL-L384A, a series of 2-substituted fumarate derivatives with
various cycloalkyloxy (12a−f), heteroaryloxy (12g−j), or
alkyloxy (12k) substituents were prepared through the
addition of appropriate alcohols to dimethyl acetylenedicar-
boxylate (10), followed by hydrolysis of the methyl esters
(Table 1). Interestingly, compounds 12a−e and 12g−k were
accepted as substrates by MAL-L384A, giving excellent
conversions (60−98%) and yielding the corresponding
amino acid products in 26−58% isolated yield (Table 1).
Hence, MAL-L384A has a remarkably broad substrate scope,
allowing the addition of ammonia to a wide variety of fumarate
derivatives, providing a powerful synthetic tool for the
preparation of valuable 3-substituted aspartic acids. The most
bulky compound, 2-cyclooctylmethoxyfumarate (12f), was not
accepted as substrate by MAL-L384A.
The amino acid product 13a, which is representative for the
series of chemoenzymatically prepared 3-cycloalkyloxy sub-
stituted aspartic acids, was identiﬁed as the desired threo
diastereomer (de = 97%, Supporting Information, Figure S1)
by comparison of its 1H NMR signals and J-coupling values to
those of an authentic standard with known L-threo conﬁg-
uration and chemically synthesized DL-threo and DL-erythro
stereoisomers (Scheme 1). To determine the absolute
conﬁguration of product 13a, HPLC analysis on a chiral
stationary phase was conducted by using corresponding
reference molecules with known L-threo or DL-threo conﬁg-
uration. This analysis revealed that chemoenzymatically
produced 13a was present as a single enantiomer with
exclusively the L-threo conﬁguration (ee > 99%, Supporting
Information, Figure S62). Similarly, the representative chemo-
enzymatic products 13g and 13k were also identiﬁed as the
desired L-threo isomers with excellent de (>98%) and ee
(>99%) values (Table 1, Supporting Information, Figures S2,
S3, S63, and S64). Although the relative conﬁgurations of
products 13b−e and 13h−j were not determined by
comparison to authentic standards, we assume the relative
conﬁgurations to be threo for all enzymatic products on the
basis of analogy.
Synthesis of (DL-threo)- and (DL-erythro)-3-Substituted
Asp derivatives. To conﬁrm the importance of the relative
conﬁguration of 3-substituted Asp derivatives for inhibition of
EAATs, representative compounds with DL-threo and DL-erythro
conﬁgurations were synthesized according to the route given in
Scheme 1. The building block (DL-threo)-16 was prepared
based on the Sharpless aminohydroxylation procedure as
previously reported.23 Compound (DL-threo)-17, with the N-
protective group transferred from Cbz to Boc, was achieved by
hydrogenolysis of (DL-threo)-16 using H2/Pd/C followed by
Boc-protection in an excellent yield (2 steps, 83%). To
Figure 1. EAAT inhibitors derived from the L-Asp scaﬀold. (A) Structures of chemoenzymatic products and designed hybrid compounds. (B)
Structures of previously developed EAAT inhibitors.
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Table 1. Three-Step Chemoenzymatic Synthesis of 3-Substituted Asp Analogues
aConversions were determined by comparing 1H NMR signals of substrates and corresponding products. bYield of isolated product after cation
exchange chromatography. cThe diastereomeric excess (de) was determined by 1H NMR. dThe puriﬁed products were tentatively assigned the
threo conﬁguration on the basis of analogy. eThe enantiomeric excess (ee) was determined by HPLC on a chiral stationary phase using authentic
standards with known L-threo and DL-threo conﬁguration (Supporting Information, Figures S62−S64). fAbsolute conﬁguration of products 13a, 13g
and 13k were determined unambiguously by comparison of 1H NMR and chiral HPLC data to those of authentic samples with known DL-erythro,
DL-threo, and L-threo conﬁguration. gn.d., not determined.
Scheme 1. Synthesis of (DL-threo)- and (DL-erythro)-3-Substituted Asp Analogues
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facilitate O-alkylation of 17 with the proper RBr, the strong
base NaH was used to deprotonate the hydroxyl group of 17,
which provided the desired (DL-threo)-18 with an isolated yield
of 11−53%.24 In addition, a small amount of epimerized
product (DL-erythro)-18 was observed and separated by ﬂash
column chromatography in 4−11% isolated yield. Subse-
Scheme 2. Synthesis of Hybrid Compounds 8 and 9a
aThe parent compounds for the blue and black parts of compound 8 are WAY-213613 (6) and L-TBOA (2), respectively, whereas the parent
compounds for the blue and black parts of compound 9 are NBI-59159 (7) and L-TBOA (2), respectively.
Table 2. Pharmacological Properties of EAAT Reference Ligands, 3-Substituted Aspartate Analogues and Hybrid Compounds
at hEAAT1, hEAAT2, hEAAT3, and rEAAT4 in the [3H]-D-Aspartate Uptake Assaya
aIC50 values are given in μM with pIC50 ± SEM in brackets, and the number of independent experiments (n) are given in superscript behind each
pIC50 ± SEM value.
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quently, global deprotection of (DL-threo)-18 was conducted
via treatment with triﬂuoroacetic acid followed by hydrolysis of
the methyl esters with LiOH, providing the desired ﬁnal
product (DL-threo)-19 with 34−39% isolated yield over two
steps. Following the same procedure, compound (DL-erythro)-
19 was obtained in 34−46% yield. Notably, (DL-threo)-19 and
(DL-erythro)-19 are not only valuable molecules for exploring
the stereochemistry−activity relationship of 3-substituted Asp
analogues as EAAT inhibitors but also for determining the
stereochemistry of the chemoenzymatically prepared products.
Design and Synthesis of Hybrid Compounds 8 and 9.
L-TBOA (2) is a potent nonselective EAAT inhibitor, while
WAY-213613 (6) and NBI-59159 (7) are EAAT2-selective
and EAAT3-preferring inhibitors, respectively (Figure
1B).17−20 We envisioned that hybridization of L-TBOA (2)
with WAY-213613 (6) or NBI-59159 (7) would result in a
synergistic eﬀect on inhibitory activity at the EAATs. Thus,
two hybrid compounds 8 and 9 were designed by integrating 2
with 6 or 7 (Figure 1A), and their synthesis was achieved
according to the route presented in Scheme 2. The multigram
scale chemoenzymatic synthesis of 2 (L-TBOA, de > 98%, ee >
99%), starting from commercially available dimethyl acetyle-
nedicarboxylate 10 and using MAL-L384A as biocatalyst, has
been previously reported.24 Selective monoesteriﬁcation at the
4-carboxylate of 2, which was accomplished under ambient
condition using one equivalent of SOCl2 in dry methanol,
delivered intermediate 20 without the need for puriﬁcation.
The 1-carboxylate of compound 20 was subsequently
protected by a tert-butyl group via treatment with BF3-Et2O/
tBuOAc, providing compound 21 with 87% isolated yield over
two steps. Starting from 21, the chiral building block 23 was
achieved in two successive reactions including Boc-protection
and selective hydrolysis of the 4-methyl ester with LiOH (two
steps, 42%). The desired Asp derivatives 8 and 9 were obtained
via amidation of 23 with appropriate amine 24 or 25 by using
EDCI/HOBT as condensation reagents followed by global
deprotection in TFA/DCM with 14−32% isolated yield over
two steps.
Pharmacological Characterization of the Asp Deriv-
atives at EAAT1−4. The pharmacological properties of the
aspartate derivatives 13a−e, 13g−k, (DL-threo)-19a−c, and
(DL-erythro)-19a−c, the hybrid molecules 8 and 9, and selected
EAAT reference ligands were determined at HEK293 cell lines
stably expressing human EAAT1, EAAT2, and EAAT3
(hEAAT1, hEAAT2, and hEAAT3, respectively) and at a
tsA201 cell line stably expressing rat EAAT4 (rEAAT4) in a
conventional [3H]-D-Asp uptake assay.25 The rank order and
absolute values of the IC50 values exhibited by the reference
EAAT substrates L-Glu, L-Asp, and (L-threo)-3-hydroxyaspar-
tate (L-THA), and the reference EAAT nonsubstrate inhibitors
DL-TBOA and WAY-213613 at the four EAATs in the [3H]-D-
Asp uptake assay were in good agreement with previously
reported pharmacological properties (Table 2).10,11,17,25−27
Overall, the 3-substituted Asp derivatives 13a−e and 13g−k
were all relatively potent inhibitors of the four EAATs, and
even though most of them displayed slightly lower IC50 values
at hEAAT1 and hEAAT2 compared to hEAAT3 and rEAAT4,
they were essentially nonselective inhibitors (Table 2). The
Asp derivatives displayed comparable high-nanomolar/low-
micromolar IC50 values at the four transporter subtypes, the
diﬀerences between the highest and lowest IC50 values in the
compound series being 5.5-, 4.9-, 13-, and 9.4-fold at hEAAT1,
hEAAT2, hEAAT3, and rEAAT4, respectively. Interestingly,
the (L-threo)-3-substituted Asp derivatives 13a−e and 13g−k
and (DL-threo)-3-substituted Asp derivatives 19a−c were
equipotent with DL-TBOA (Table 2). On the basis of direct
comparisons between racemic Asp analogues (DL-threo)-19a−c
and (DL-erythro)-19a−c, it is clear that the (DL-threo)-Asp
analogues were signiﬁcantly more potent inhibitors than the
corresponding (DL-erythro)-Asp analogues at all four EAAT
subtypes (Table 2). Notably, the enantiopure Asp derivatives
(L-threo)-13a,g,k only displayed slightly lower IC50 values than
their racemic counterparts (DL-threo)-19a−c (Table 2). These
results are in line with previous observations that L-TBOA and
L-TFB-TBOA were more potent inhibitors of EAATs than
their corresponding (L-erythro)-diastereomers.11,28 These
structure−activity relationships thus demonstrate that essen-
tially every (cyclo)alkyloxy and (hetero)aryloxy substituent in
the 3-position of Asp yields a potent EAAT inhibitor and also
conﬁrm that the relative threo conﬁguration of 3-substituted
Asp analogues is crucial for their inhibitory activities at EAATs.
The retained EAAT inhibitory activity in the Asp analogues
13a−e and 13g−k regardless of the size of their respective 3-
substituent contrasts the substantial gradual reduction in
EAAT activity observed upon the introduction of 4-
substituents of increasing size into Glu.29,30 It seems
reasonable to ascribe these SAR diﬀerences to the substituents
in the 3-substituted Asp analogue and the 4-substituted Glu
analogue projecting out into diﬀerent regions of the EAAT
substrate binding pocket. Perhaps more interesting, the
complete lack of subtype-selectivity or -preference exhibited
by all of the analogues in this study (13a−e and 13g−k) diﬀers
remarkably from our recent ﬁndings for a series of sulfonamido
functionalized 3-substituted aspartate analogues that comprises
both EAAT1-preferring and EAAT2-selective inhibitors.16 It
seems that even when comparing diﬀerent 3-substituted Asp
analogues, diﬀerent functionalities (an ether vs a sulfonamide
group) in this position of the Asp molecule will result in the
substituents being projected out into diﬀerent binding pocket
regions, which again is reﬂected in markedly diﬀerent subtype-
selectivity proﬁles across the EAATs.
Whereas Asp (both L-Asp and D-Asp) and its derivative (L-
threo)-3-hydroxy Asp (L-THA) are substrates for EAAT1−4,
the (DL-threo)-3-benzyloxy Asp (DL-TBOA) analogue is a
nonsubstrate inhibitor of all four EAAT subtypes.10,11,17,25−27
Because the series of Asp analogues in the present study
comprised analogues with 3-substituents covering a consid-
erable spectrum in terms of sizes, we decided to test these
analogues for both substrate and nonsubstrate inhibitor activity
at the hEAAT1−3 cell lines in the ﬂuorescence-based FLIPR
Membrane Potential Blue (FMP) assay. This assay measures
the membrane potential changes induced in the cell lines by
the substrate translocation and the concomitant cotransport of
Na+, H+, and the counter-transport of K+ mediated by the
EAAT. In a previous study, we have found the assay to be
capable of distinguishing substrates from nonsubstrate
inhibitors within a series of reference EAAT ligands.25 None
of the 3-substituted Asp analogues (13a−e and 13g−k) were
substrates at hEAAT1−3, as they did not evoke a signiﬁcant
increase in the ﬂuorescence levels in the assay when applied on
their own (all at concentrations of 300 μM) at hEAAT1-,
hEAAT2-, and hEAAT3-HEK293 cell lines (data not shown).
In contrast, preincubation and coapplication of the analogues
(all at concentrations of 300 μM) together with L-Glu EC80
completely eliminated the Glu-induced response at all three
transporters (data not shown), and thus all 3-substituted Asp
Journal of Medicinal Chemistry Article
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analogues were nonsubstrate inhibitors of the EAATs. Given
that L-THA is a substrate for EAAT1−4, these ﬁndings clearly
demonstrate that the borderline between when the Asp
analogue can be transported by the EAAT or not lies right
between the 3-hydroxy substituent (L-THA) and 3-substitu-
ents such as cyclopropyl (13a), prop-2-yn (13k), and larger
groups in the series of Asp analogues tested here (Figure 1,
Table 2).
The IC50 values displayed by the TBOA/WAY-213613
hybrid, compound 8, at hEAAT1, hEAAT2, hEAAT3, and
rEAAT4 in the [3H]-D-Asp uptake assay were 190-, 53-, 40-,
and 16-fold lower than those of DL-TBOA and 78-, 2.0-, 20-,
and 11-fold lower than those of WAY-213613 (6), respectively
(Table 2, Figure 2). Thus, introduction of a benzyloxy group
into the 3-position of WAY213613 converts this EAAT2-
selective inhibitor into a nonselective but much more potent
EAAT inhibitor. Hybrid compound 9, derived from TBOA (2)
and NBI-59159 (7), displayed IC50 values of 12, 47, 55, and 80
nM and was thus 180-, 40-, 69-, and 29-fold more potent as
inhibitor at hEAAT1, hEAAT2, hEAAT3, and rEAAT4,
respectively, than DL-TBOA. Because we did not test NBI-
59159 (7) in the [3H]-D-Asp uptake assay, we cannot make a
direct comparison between the inhibitory potencies displayed
by 9 and those of this other parent compound. However,
compared to the reported inhibitory data of NBI-59159 (7),19
the hybrid analogue 9 displayed 83-, 30-, and 1.6-fold increased
inhibitory potencies at EAAT1, EAAT2, and EAAT3,
respectively (Table 2, Figure 2). Analogously to the
observation for the hybrid analogue 8 and its parent compound
WAY-213613, introducing a benzyloxy group at the 3-position
of NBI-59159 converted this EAAT3-preferring inhibitor into a
nonselective but considerably more potent EAAT inhibitor.
The chemoenzymatic synthesis of L-TFB-TBOA (3a) and its
four derivatives 3b−e was reported elsewhere.24 In agreement
with the original study of L-TFB-TBOA,12 the chemoenzymati-
cally prepared compound 3a was found to be a potent EAAT
inhibitor displaying IC50 values of 3.6, 10, 120, and 40 nM at
hEAAT1, hEAAT2, hEAAT3, and rEAAT4, respectively, thus
displaying some preference for hEAAT1,2 over hEAAT3
(Table 2). Whereas substitution of the p-CF3 group in L-TFB-
TBOA with o-CF3 (3b) resulted in signiﬁcantly decreased
inhibitory potencies at the EAATs, the m-CF3 analogue (3c)
displayed comparable IC50 values as L-TFB-TBOA (3a) at all
four transporter subtypes. While extension of the functional
group at the C-3 position in L-TFB-TBOA with one carbon
(3d) resulted in 5−10-fold increased IC50 values at hEAAT1,
hEAAT2, and rEAAT4, the homologue retained the inhibitory
potency of L-TFB-TBOA at hEAAT3. Interestingly, extension
of the C-3 functional group with two carbons resulted in a
homologue (3e) with similar inhibitory properties at the four
EAATs as L-TFB-TBOA (Table 2).
■ CONCLUSION
We have presented the design, synthesis, and pharmacological
characterization of an elaborate series of 3-substituted Asp
analogues as inhibitors of hEAAT1, hEAAT2, hEAAT3, and
rEAAT4. Inspired by the potential of the Asp scaﬀold for the
development of EAAT inhibitors, various new Asp derivatives
with (cyclo)alkyloxy and (hetero)aryloxy substituents at the C-
3 position were synthesized by using a key stereoselective
enzymatic step. Remarkably, all these Asp derivatives were
Figure 2. Functional properties of the hybrid analogues 8 and 9 as EAAT inhibitors. Representative concentration−inhibition curves for 8, 9, DL-
TBOA (parent compound of both 8 and 9), and WAY-213613 (6, parent compound of 8) at hEAAT1-HEK293, hEAAT2-HEK293, hEAAT3-
HEK293, and rEAAT4-tsA201 cells in the [3H]-D-Asp uptake assay. Data are from a representative speciﬁc experiment and given as mean ± SD
values (based on duplicate determinations).
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found to be potent nonsubstrate pan inhibitors of the EAATs.
The functional properties exhibited by the Asp analogues also
provide insight into the relation between ligand structure and
EAAT transport. Whereas Asp and (L-threo)-3-hydroxy Asp (L-
THA) are substrates of EAATs, it is clear from this series that
basically any Asp derivative with a substituent at C-3 larger
than a hydroxyl group will be a nonsubstrate inhibitor. Because
all of these compounds are Asp derivatives, it is reasonable to
assume that they function as competitive inhibitors, like DL-
TBOA,25 and act through the substrate binding site in the
transporters. On the other hand, judging from the fact that all
3-substituted Asp analogues comprising a wide range of
substituents displayed comparable inhibitory potencies, the 3-
substituent either does not contribute substantially to this
inhibitory potency by forming interactions with residues in the
substrate binding site of the transporter or alternatively all of
the 3-substituents in the tested analogues are able to form
similar interactions. Finally, our results conﬁrm that the threo
conﬁguration of the 3-substituted Asp analogue is crucial for its
high inhibitory activities at EAATs.
Unique EAAT inhibitors were developed by hybridization of
the nonselective EAAT inhibitor L-TBOA (2) with the
EAAT2-selective inhibitor WAY-213613 or the EAAT3-
preferring inhibitor NBI-59159 to yield hybrid analogues 8
and 9, respectively. Compounds 8 and 9 displayed signiﬁcantly
higher inhibitory activities at EAATs than both of their
respective parent structures, although the hybridization in both
cases leads to pan inhibitors of EAAT1−4. Thus, while the
additional interactions with the transporter formed by the
benzyloxy group at the 3-position in 8/9 in both cases leads to
increased inhibitory potency, it also seems to induce a binding
conformation of the Asp analogue that dictates a diﬀerent
spatial orientation of the 4-(2-bromo-4,5-diﬂuorophenoxy)-
phenyl/(9H-ﬂuoren-2-yl) substituent than in WAY-213613/
NBI-59159. We propose that this and other hybridization
strategies could advance future design and development of
more potent EAAT inhibitors.
We recently reported the synthesis and evaluation of L-TFB-
TBOA-based inhibitors of the prokaryotic aspartate transporter
GltTk with photocontrolled activity, allowing the remote,
reversible, and spatiotemporally resolved regulation of trans-
port.31 Work is in progress to convert the hybrid compounds 8
and 9, which were shown here to be highly potent nonselective
EAAT inhibitors, into light-controlled glutamate transporter
inhibitors by introducing a photoswitchable azobenzene
moiety.
■ EXPERIMENTAL SECTION
Chemicals and General Methods. All chemicals were purchased
from commercial sources unless otherwise speciﬁed. All the solvents
were of analytical reagent grade and were used without further
puriﬁcation. 1H NMR, 13C NMR, and 19F NMR analysis were
performed on a Bruker Avance III 400/500 MHz spectrometer. High
resolution mass spectra (HRMS) were recorded on a LTQ Orbitrap
XL. Flash chromatography was performed on a GRACE X2 system
with silica gel (200−300 mesh) purchased from Merck. High
performance liquid chromatography (HPLC) analysis was performed
with a Shimadzu LC-10AT HPLC with a Shimadzu SP-M10A ELSD
detector and a Shimadzu SPD-M10A photodiode array detector.
Analytical HPLC was performed using a Kinetex C18 column (150
mm × 4.6 mm, 5 μm) with 5−95% MeCN gradient in H2O (0.5%
TFA) as mobile phase. The purity of all the target compounds was
determined to be >95%. Chiral HPLC analysis for compound 13g was
perfomed using Nucleosil Chiral-1 column (250 mm × 4 mm, 5 μm)
with 0.5 mM aqueous CuSO4 as mobile phase. Chiral HPLC analysis
for compounds 13a and 13k was perfomed using CROWNPAK CR-I
(+) column (150 mm × 3 mm, 5 μm) with isocratic MeCN/H2O
(98%, v/v, 0.5% TFA) as mobile phase.
Synthesis of Hybrid Compounds 8 and 9. (L-threo)-2-Amino-
3-(benzyloxy)-4-[[4-(2-bromo-4,5-diﬂuorophenoxy)phenyl]amino]-
4-oxobutanoic Acid (8). To a stirred solution of 26 (68 mg, 0.1
mmol, see below) in dry DCM (2 mL), in an ice-bath, was added
triﬂuoroacetic acid (2 mL) dropwise. After the complete addition of
triﬂuoroacetic acid, the ice-bath was removed and the reaction was
allowed to proceed at room temperature for further 6 h. After
completion of the starting material, the solvent was removed in vacuo
to provide pure 8 as a triﬂuoroacetate salt (brown solid, 34 mg, yield
52%). 1H NMR (500 MHz, D2O/DMSO-d6): δ 7.74 (dd, J = 9.8, 8.3
Hz, 1H), 7.43−7.41 (m, 2H), 7.32−7.25 (m, 5H), 7.10−7.02 (m,
1H), 6.89−6.88 (m, 2H), 4.62−4.56 (m, 2H), 4.46 (d, J = 4.0 Hz,
1H), 4.16 (d, J = 3.9 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ
168.1, 166.4, 152.4, 149.5 (dd, J = 8.2, 3.8 Hz), 148.5 (dd, J = 374.9,
13.9 Hz), 148.6 (dd, J = 372.3, 13.9 Hz), 136.9, 134.2, 128.2 (2C),
128.0 (2C), 127.9, 122.0, 121.9, 117.8 (2C), 115.3 (d, J = 21.4 Hz),
110.2 (d, J = 20.2 Hz), 108.6 (dd, J = 7.6, 3.8 Hz), 76.8, 72.1, 54.1.
19F NMR (376 MHz, DMSO-d6): δ −73.51 (s), −134.99 (dt, J =
20.6, 10.1 Hz), −141.25 (dt, J = 23.2, 9.0 Hz). HRMS: calcd for
C23H20BrF2N2O5 [M + H]
+ 521.0518, found 521.0520. HPLC: purity
98%, retention time 9.0 min.
(L-threo)-4-[(9H-Fluoren-2-yl)amino]-2-amino-3-(benzyloxy)-4-
oxobutanoic Acid (9). Hybrid compound 9 was prepared from 27
(100 mg, 0.18 mmol, see below) following a procedure similar to that
used for compound 8. The title product was obtained as a white solid
(32 mg, 35%). 1H NMR (500 MHz, DMSO-d6): δ 10.35 (s, 1H), 7.99
(s, 1H), 7.84 (t, J = 7.8 Hz, 2H), 7.58 (dd, J = 13.4, 7.9 Hz, 2H), 7.42
(d, J = 7.3 Hz, 2H), 7.38−7.34 (m, 3H), 7.32−7.27 (m, 2H), 4.70 (d,
J = 11.7 Hz, 1H), 4.63 (d, J = 4.1 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H),
4.06 (bs, 1H), 3.92 (s, 2H). 13C NMR (126 MHz, methanol-d4): δ
169.5, 168.4, 145.4, 144.5, 142.4, 140.0, 138.7, 137.7, 137.4, 129.7
(2C), 129.6, 127.9, 127.7, 126.0, 121.0, 120.6, 120.5, 118.6, 107.3,
77.7, 74.6, 56.1, 37.7. HRMS: calcd for C24H23N2O4 [M + H]
+
403.1652, found 403.1653. HPLC: purity 98%, retention time 8.4
min.
Synthesis of Dimethyl 2-Substituted Fumarate Derivatives
11a−k. The synthesis of the dimethyl 2-substituted fumarate
derivatives 11a−k was based on a previously published procedure.22,32
Brieﬂy, to a stirred solution of dimethyl acetylenedicarboxylate (10,
568 mg, 4 mmol) in dichloromethane (30 mL) was added DABCO
(45 mg, 0.4 mmol) followed by the appropriate alcohol (5 mmol).
The reaction mixture was stirred at room temperature for 12 h. The
solvent was removed under reduced pressure to give the crude
product as a dark-brown oil. The trans/cis isomers of the products
were separated by ﬂash chromatography (silica gel) using 5% EtOAc/
petroleum ether (boiling point 40−60 °C) as eluent. The preferred
trans-isomers 11a−k (i.e., the fumarate derivatives) were used in
further experiments.
Dimethyl 2-(Cyclopropylmethoxy)fumarate (11a). Clear oil, 230
mg (27% yield). 1H NMR (500 MHz, CDCl3): δ 6.11 (s, 1H), 3.84
(d, J = 7.2 Hz, 2H), 3.72 (s, 3H), 3.63 (s, 3H), 1.16−1.08 (m, 1H),
0.49−0.45 (m, 2H), 0.21−0.18 (m, 2H). 13C NMR (126 MHz,
CDCl3): δ 164.5, 163.4, 154.1, 109.6, 78.4, 52.6, 51.4, 10.6, 3.0 (2C).
Dimethyl 2-(Cyclobutylmethoxy)fumarate (11b). Clear oil, 164
mg (18% yield). 1H NMR (500 MHz, CDCl3): δ 6.11 (s, 1H), 4.00
(d, J = 6.7 Hz, 2H), 3.77 (s, 3H), 3.68 (s, 3H), 2.69−2.61 (m, 1H),
2.04−1.97 (m, 2H), 1.87−1.76 (m, 4H). 13C NMR (126 MHz,
CDCl3): δ 164.7, 163.4, 154.5, 108.9, 77.6, 52.7, 51.5, 35.1, 24.5
(2C), 18.3.
Dimethyl 2-(Cyclopentylmethoxy)fumarate (11c). Clear oil, 136
mg (14% yield). 1H NMR (500 MHz, CDCl3): δ 6.15 (s, 1H), 3.96
(d, J = 6.9 Hz, 2H), 3.82 (s, 3H), 3.74 (s, 3H), 2.34−2.25 (m, 1H),
1.81−1.75 (m, 2H), 1.62−1.53 (m, 4H), 1.35−1.29 (m, 2H). 13C
NMR (126 MHz, CDCl3): δ 164.9, 163.7, 154.7, 108.6, 78.0, 52.9,
51.8, 39.8, 29.2 (2C), 25.6 (2C).
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Dimethyl 2-(Cyclohexylmethoxy)fumarate (11d). Clear oil, 130
mg (13% yield). 1H NMR (500 MHz, CDCl3): δ 6.13 (s, 1H), 3.88
(d, J = 6.4 Hz, 2H), 3.82 (s, 3H), 3.74 (s, 3H), 1.84−1.66 (m, 6H),
1.30−1.14 (m, 3H), 1.05−0.97 (m, 2H). 13C NMR (126 MHz,
CDCl3): δ 165.0, 163.7, 154.9, 108.1, 79.4, 52.9, 51.8, 38.5, 29.6
(2C), 26.6, 25.9 (2C).
Dimethyl 2-(Cycloheptylmethoxy)fumarate (11e). Clear oil, 83
mg (8% yield). 1H NMR (500 MHz, CDCl3): δ 6.12 (s, 1H), 3.85 (d,
J = 6.6 Hz, 2H), 3.81 (s, 3H), 3.72 (s, 3H), 1.93−1.86 (m, 1H),
1.83−1.77 (m, 2H), 1.69−1.63 (m, 2H), 1.58−1.54 (m, 2H), 1.51−
1.39 (m, 4H), 1.27−1.20 (m, 2H). 13C NMR (126 MHz, CDCl3): δ
164.9, 163.6, 154.7, 108.3, 79.2, 52.9, 51.7, 39.9, 30.7 (2C), 28.6
(2C), 26.5 (2C).
Dimethyl 2-(Cyclooctylmethoxy)fumarate (11f). Clear oil, 56 mg
(5% yield). 1H NMR (500 MHz, CDCl3): δ 6.12 (s, 1H), 3.85 (d, J =
6.6 Hz, 2H), 3.82 (s, 3H), 3.73 (s, 3H), 1.97−1.91 (m, 1H), 1.74−
1.65 (m, 4H), 1.62−1.46 (m, 8H), 1.36−1.28 (m, 2H). 13C NMR
(126 MHz, CDCl3): δ 164.9, 163.7, 154.8, 108.2, 79.6, 52.9, 51.7,
38.2, 29.1 (2C), 27.0 (2C), 26.5, 25.5 (2C).
Dimethyl 2-(Thiophen-3-ylmethoxy)fumarate (11g). Light-yellow
solid, 275 mg (27% yield). 1H NMR (500 MHz, CDCl3): δ 7.35−
7.34 (m, 1H), 7.30 (dd, J = 5.0, 3.0 Hz, 1H), 7.16 (dd, J = 5.0, 1.3 Hz,
1H), 6.23 (s, 1H), 5.22 (s, 2H), 3.82 (s, 3H), 3.74 (s, 3H). 13C NMR
(126 MHz, CDCl3): δ 164.7, 163.4, 153.6, 137.2, 127.6, 126.3, 124.6,
110.4, 70.2, 53.0, 51.8.
Dimethyl 2-(Thiophen-2-ylmethoxy)fumarate (11h). Light-yel-
low solid, 310 mg (38% yield). 1H NMR (500 MHz, CDCl3): δ 7.33
(dd, J = 5.1, 1.2 Hz, 1H), 7.08 (d, J = 3.4 Hz, 1H), 6.98 (dd, J = 5.1,
3.5 Hz, 1H), 6.28 (s, 1H), 5.37 (s, 2H), 3.83 (s, 3H), 3.75 (s, 3H).
13C NMR (126 MHz, CDCl3): δ 164.7, 163.4, 153.0, 138.1, 128.53,
127.4, 126.9, 111.5, 69.2, 53.0, 51.9.
Dimethyl 2-(Furan-3-ylmethoxy)fumarate (11i). Light-yellow
solid, 345 mg (36% yield). 1H NMR (500 MHz, CDCl3): δ 7.46
(dd, J = 1.7, 0.9 Hz, 1H), 7.39 (t, J = 1.7 Hz, 1H), 6.49 (d, J = 1.2 Hz,
1H), 6.24 (s, 1H), 5.10 (s, 2H), 3.82 (s, 3H), 3.74 (s, 3H). 13C NMR
(126 MHz, CDCl3): δ 164.7, 163.5, 153.5, 143.6, 141.8, 120.8, 110.6
(2C), 66.6, 53.0, 51.8.
Dimethyl 2-(Furan-2-ylmethoxy)fumarate (11j). Light-yellow
solid, 382 mg (40% yield). 1H NMR (500 MHz, CDCl3): δ 7.42
(dd, J = 1.9, 0.9 Hz, 1H), 6.41 (d, J = 3.3 Hz, 1H), 6.35 (dd, J = 3.3,
1.8 Hz, 1H), 6.29 (s, 1H), 5.17 (s, 2H), 3.83 (s, 3H), 3.73 (s, 3H).
13C NMR (126 MHz, CDCl3): δ 164.6, 163.4, 153.0, 149.7, 143.7,
111.4, 111.3, 110.6, 66.7, 53.0, 51.7.
Dimethyl 2-(Prop-2-yn-1-yloxy)fumarate (11k). Clear oil, 295 mg
(37% yield). 1H NMR (500 MHz, CDCl3): δ 6.35 (s, 1H), 4.90 (d, J
= 2.5 Hz, 2H), 3.84 (s, 3H), 3.75 (s, 3H), 2.55 (t, J = 2.5 Hz, 1H).
13C NMR (126 MHz, CDCl3): δ 164.5, 163.2, 152.0, 111.6, 82.9,
77.1, 60.4, 53.1, 52.0.
Synthesis of 2-Substituted Fumaric Acid Derivatives 12a−k.
To a stirred solution of dimethyl 2-substituted fumarate 11 (11a, 214
mg, 1.0 mmol; 11b, 150 mg, 0.66 mmol; 11c, 121 mg, 0.50 mmol;
11d, 115 mg, 0.45 mmol; 11e, 70 mg, 0.26 mmol; 11f, 56 mg, 0.20
mmol; 11g, 112 mg, 0.44 mmol; 11h, 87 mg, 0.34 mmol; 11i, 62 mg,
0.26 mmol; 11j, 70 mg, 0.30 mmol; 11k, 198 mg, 1.0 mmol,
respectively) in EtOH (2 mL) was added 2 M NaOH (2 mL), and the
reaction mixture was heated to reﬂux for 2 h. After completion of the
hydrolysis, the reaction mixture was allowed to cool to room
temperature followed by removing the EtOH under vacuum. For
compounds 11a−f and 11k, the resulting aqueous layer was acidiﬁed
with HCl (1 M) until white precipitates appeared (pH 1). The
precipitates were ﬁltered and dried under vacuum to provide pure
products 12a−f and 12k as white solids. For compounds 12g−j, the
resulting aqueous solutions were directly used for the next enzymatic
step after adjusting the pH of the solution to pH 9.5 with 1 M HCl.
2-(Cyclopropylmethoxy)fumaric Acid (12a). White solid, 150 mg
(81% yield). 1H NMR (500 MHz, DMSO-d6): δ 6.02 (s, 1H), 3.85
(d, J = 7.1 Hz, 2H), 1.13−1.07 (m, 1H), 0.51−0.47 (m, 2H), 0.25−
0.22 (m, 2H). 13C NMR (126 MHz, DMSO-d6): δ 165.4, 164.2,
153.8, 109.8, 76.8, 10.6, 3.0 (2C).
2-(Cyclobutylmethoxy)fumaric Acid (12b). White solid, 110 mg
(84% yield). 1H NMR (500 MHz, methanol-d4): δ 6.07 (s, 1H), 4.02
(d, J = 5.6 Hz, 2H), 2.68−2.62 (m, 1H), 2.04−2.00 (m, 2H), 1.91−
1.83 (m, 4H). 13C NMR (126 MHz, methanol-d4): δ 167.9, 165.8,
156.5, 110.0, 78.2, 36.6, 25.5 (2C), 19.2.
2-(Cyclopentylmethoxy)fumaric Acid (12c). White solid, 77 mg
(72% yield). 1H NMR (500 MHz, methanol-d4): δ 6.00 (s, 1H), 3.90
(d, J = 7.0 Hz, 2H), 2.24−2.15 (m, 1H), 1.72−1.66 (m, 2H), 1.57−
1.47 (m, 4H), 1.31−1.23 (m, 2H). 13C NMR (126 MHz, methanol-
d4): δ 168.0, 165.8, 156.7, 109.3, 78.4, 41.0, 30.1 (2C), 26.4 (2C).
2-(Cyclohexylmethoxy)fumaric Acid (12d). White solid, 78 mg
(76% yield). 1H NMR (500 MHz, DMSO-d6): δ 5.93 (s, 1H), 3.81
(d, J = 6.4 Hz, 2H), 1.74−1.56 (m, 6H), 1.24−1.10 (m, 3H), 1.00−
0.92 (m, 2H). 13C NMR (126 MHz, DMSO-d6): δ 165.8, 164.6,
154.8, 108.5, 78.2, 38.3, 29.3 (2C), 26.3, 25.6 (2C).
2-(Cycloheptylmethoxy)fumaric Acid (12e). White solid, 42 mg
(67% yield). 1H NMR (500 MHz, methanol-d4): δ 6.05 (s, 1H), 3.86
(d, J = 6.4 Hz, 2H), 1.88−1.78 (m, 3H), 1.70−1.65 (m, 2H), 1.60−
1.43 (m, 6H), 1.29−1.23 (m, 2H). 13C NMR (126 MHz, methanol-
d4): δ 168.0, 165.8, 156.5, 109.1, 79.6, 41.1, 31.7 (2C), 29.7 (2C),
27.5 (2C).
2-(Cyclooctylmethoxy)fumaric Acid (12f). White solid, 20 mg
(39% yield). 1H NMR (500 MHz, methanol-d4): δ 6.03 (s, 1H), 3.82
(d, J = 6.7 Hz, 2H), 1.93−1.86 (m, 1H), 1.72−1.64 (m, 4H), 1.59−
1.44 (m, 8H), 1.33−1.27 (m, 2H). 13C NMR (126 MHz, methanol-
d4): δ 168.0, 165.8, 156.6, 109.0, 80.1, 39.3, 30.2 (2C), 28.0 (2C),
27.7, 26.5 (2C).
Disodium 2-(Thiophen-3-ylmethoxy)fumarate (12g). 1H NMR
(500 MHz, DMSO-d6): δ 7.53−7.50 (m, 2H), 7.15 (dd, J = 4.9, 1.3
Hz, 1H), 6.05 (s, 1H), 5.10 (s, 2H). 13C NMR (126 MHz, DMSO-
d6): δ 165.3, 164.0, 153.5, 137.7, 127.6, 126.6, 124.2, 110.2, 69.1.
Disodium 2-(Thiophen-2-ylmethoxy)fumarate (12h). 1H NMR
(500 MHz, D2O): δ 7.42 (dd, J = 5.0, 1.3 Hz, 1H), 7.08−7.05 (m,
1H), 7.00 (dd, J = 5.1, 3.5 Hz, 1H), 5.91 (s, 1H), 5.14 (s, 2H). 13C
NMR (126 MHz, D2O): δ 173.9, 170.9, 152.4, 138.7, 128.6, 127.5,
126.9, 114.4, 66.6.
Disodium 2-(Furan-3-ylmethoxy)fumarate (12i). 1H NMR (500
MHz, D2O): δ 7.50 (dd, J = 1.6, 0.8 Hz, 1H), 7.44 (t, J = 1.9 Hz, 1H),
6.49 (s, 1H), 5.89 (s, 1H), 4.85 (s, 2H). 13C NMR (126 MHz, D2O):
δ 174.0, 171.0, 152.7, 143.6, 142.0, 120.8, 113.8, 110.6, 63.8.
Disodium 2-(Furan-2-ylmethoxy)fumarate (12j). 1H NMR (500
MHz, D2O): δ 7.45 (dd, J = 1.9, 0.8 Hz, 1H), 6.38 (dd, J = 3.3, 0.8
Hz, 1H), 6.36 (dd, J = 3.3, 1.9 Hz, 1H), 5.91 (s, 1H), 4.89 (s, 2H).
13C NMR (126 MHz, D2O): δ 173.8, 170.8, 152.2, 150.0, 143.8,
114.6, 111.2, 110.5, 64.2.
2-(Prop-2-yn-1-yloxy)fumaric Acid (12k). White solid, 142 mg
(83% yield). 1H NMR (500 MHz, DMSO-d6): δ 6.14 (s, 1H), 4.82
(d, J = 2.5 Hz, 2H), 3.63 (t, J = 2.5 Hz, 1H). 13C NMR (126 MHz,
DMSO-d6): δ 165.1, 163.7, 151.8, 111.7, 79.4, 78.4, 59.1.
Enzymatic Synthesis of 3-Substituted Aspartic Acid
Derivatives 13a−k. Reaction mixtures consisted of 2-substituted
fumaric acid derivatives 12 (12a, 21 mg, 0.11 mmol; 12b, 40 mg, 0.20
mmol; 12c, 42 mg, 0.20 mmol; 12d, 28 mg, 0.12 mmol; 12e, 23 mg,
0.095 mmol; 12f, 12 mg, 0.047 mmol; 12g, 0.44 mmol; 12h, 0.34
mmol; 12i, 0.26 mmol; 12j, 0.30 mmol; 12k, 9.7 mg, 0.056 mmol,
respectively) in buﬀer (5 M NH3/NH4Cl and 20 mM MgCl2, pH
adjusted to pH 9.5). The reaction was started by addition of freshly
puriﬁed MAL-L384A mutant (0.01 mol %),21,22 and the reaction
mixture was incubated at room temperature for 24 h. After
completion of the reaction, the enzyme was inactivated by heating
to 70 °C for 10 min. The progress and conversion yield of the
enzymatic reaction was monitored by 1H NMR spectroscopy by
comparing signals of substrates and corresponding products. For a
typical puriﬁcation procedure, the precipitated enzyme was removed
by ﬁltration. The ﬁltrate was acidiﬁed with 1 M HCl to pH 1 and
loaded onto a column packed with cation-exchange resin (10 g of
Dowex 50W X8, 50−100 mesh), which was pretreated with 2 M
aqueous ammonia (4 column volumes), 1 M HCl (2 column
volumes), and distilled water (4 column volumes). The column was
washed with distilled water (2 column volumes), and the desired
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product was eluted with 2 M aqueous ammonia (4 column volumes).
The ninhydrin-positive fractions were collected and lyophilized to
yield the product as ammonium salt.
(L-threo)-3-(Cyclopropylmethoxy)aspartate (13a). White solid, 7
mg (conversion 88%, isolated yield 31%). 1H NMR (500 MHz,
D2O): δ 4.38 (d, J = 2.5 Hz, 1H), 3.98 (d, J = 2.5 Hz, 1H), 3.45 (dd, J
= 10.7, 7.0 Hz, 1H), 3.28 (dd, J = 10.7, 7.2 Hz, 1H), 1.05−0.97 (m,
1H), 0.53−0.46 (m, 2H), 0.20−0.15 (m, 2H). 13C NMR (126 MHz,
D2O): δ 176.1, 171.6, 77.4, 75.7, 56.6, 9.5, 2.6, 2.1. HRMS: calcd for
C8H14NO5 [M + H]
+ 204.0866, found 204.0861. HPLC: purity 96%,
retention time 4.2 min. Comparison of the 1H NMR data of 13a with
the 1H NMR data of chemically prepared racemic (DL-threo)-19a and
(DL-erythro)-19a showed that the de of product 13a was 97%
(Supporting Information, Figure S1). Chiral HPLC analysis:
Crownpak CR-I (+) 150 mm × 3 mm. Phase A, ACN + 0.5%
TFA; phase B, H2O + 0.5% TFA, A/B = 98:2. Flow rate 0.4 mL/min,
column temperature 25 °C, detected by ELSD at 35 °C, tR = 2.8 min,
ee > 99% (Supporting Information, Figure S62).
3-(Cyclobutylmethoxy)aspartate (13b). White solid, 25 mg
(conversion 89%, isolated yield 58%). 1H NMR (500 MHz, D2O):
δ 4.24 (d, J = 2.4 Hz, 1H), 3.95 (d, J = 2.4 Hz, 1H), 3.60 (dd, J = 9.8,
6.8 Hz, 1H), 3.39 (dd, J = 9.8, 7.3 Hz, 1H), 2.56−2.47 (m, 1H),
2.01−1.95 (m, 2H), 1.86−1.77 (m, 2H), 1.68−1.61 (m, 2H). 13C
NMR (126 MHz, D2O): δ 176.4, 171.7, 78.3, 75.6, 56.5, 34.1, 24.5,
24.2, 18.0. HRMS: calcd for C9H16NO5 [M + H]
+ 218.1023, found
218.1022. HPLC: purity 98%, retention time 6.5 min.
3-(Cyclopentylmethoxy)aspartate (13c). White solid, 19 mg
(conversion 85%, isolated yield 39%). 1H NMR (500 MHz, D2O):
δ 4.28 (d, J = 2.5 Hz, 1H), 3.98 (d, J = 2.5 Hz, 1H), 3.54 (dd, J = 9.4,
7.0 Hz, 1H), 3.25 (dd, J = 9.4, 7.7 Hz, 1H), 2.17−2.11 (m, 1H),
1.70−1.63 (m, 2H), 1.56−1.47 (m, 4H), 1.22−1.13 (m, 2H). 13C
NMR (126 MHz, D2O): δ 176.2, 171.5, 78.2, 75.7, 56.4, 38.5, 28.9,
28.7, 24.9 (2C). HRMS: calcd for C10H18NO5 [M + H]
+ 232.1180,
found 232.1180. HPLC: purity 97%, retention time 9.3 min.
3-(Cyclohexylmethoxy)aspartate (13d). White solid, 17 mg
(conversion 90%, isolated yield 56%). 1H NMR (500 MHz, D2O):
δ 4.28 (d, J = 2.6 Hz, 1H), 3.99 (d, J = 2.5 Hz, 1H), 3.48 (dd, J = 9.6,
6.3 Hz, 1H), 3.20 (dd, J = 9.6, 6.9 Hz, 1H), 1.69−1.55 (m, 6H),
1.25−1.11 (m, 3H), 0.91−0.85 (m, 2H). 13C NMR (126 MHz, D2O):
δ 175.9, 171.3, 78.1, 76.9, 56.3, 37.0, 29.3, 29.1, 26.1, 25.2 (2C).
HRMS: calcd for C11H20NO5 [M + H]
+ 246.1336, found 246.1336.
HPLC: purity 98%, retention time 7.8 min.
3-(Cycloheptylmethoxy)aspartate (13e). White solid, 7 mg
(conversion 60%, isolated yield 26%). 1H NMR (500 MHz, D2O):
δ 4.27 (d, J = 2.1 Hz, 1H), 3.97 (d, J = 2.2 Hz, 1H), 3.45 (dd, J = 9.5,
6.6 Hz, 1H), 3.17 (dd, J = 9.5, 7.2 Hz, 1H), 1.79−1.72 (m, 1H),
1.69−1.58 (m, 4H), 1.55−1.52 (m, 2H), 1.49−1.37 (m, 4H), 1.17−
1.09 (m, 2H). 13C NMR (126 MHz, D2O): δ 176.2, 171.4, 78.2, 76.5,
56.4, 38.3, 30.3 (2C), 28.2 (2C), 25.9 (2C). HRMS: calcd for
C12H22NO5 [M + H]
+ 260.1492, found 260.1494. HPLC: purity 95%,
retention time 10.0 min.
(L-threo)-3-(Thiophen-3-ylmethoxy)aspartate (13g). Light-yellow
solid, 47 mg (conversion 98%, isolated yield 47%). 1H NMR (500
MHz, D2O): δ 7.43−7.42 (m, 1H), 7.39−7.38 (m, 1H), 7.11 (dd, J =
4.9, 1.3 Hz, 1H), 4.70 (d, J = 11.9 Hz, 1H), 4.50 (d, J = 11.9 Hz, 1H),
4.29 (d, J = 2.2 Hz, 1H), 3.96 (d, J = 2.2 Hz, 1H). 13C NMR (126
MHz, D2O): δ 175.8, 171.4, 137.7, 127.8, 126.6, 124.7, 77.0, 67.2,
56.5. HRMS: calcd for C9H12NO5 [M + H]
+ 246.0431, found
246.0430. HPLC: purity 99%, retention time 5.2 min. Comparison of
the 1H NMR data of 13g with the 1H NMR data of chemically
prepared racemic racemic (DL-threo)-19b and (DL-erythro)-19b
showed that the de of product 13g was >98% (Supporting
Information, Figure S2). Chiral HPLC conditions: Nucleosil chiral-
1 column with 0.5 mM aqueous CuSO4 solution as mobile phase with
a ﬂow rate of 1.0 mL/min at 60 °C, UV detection at 254 nm, tR = 7.2
min, ee > 99% (Supporting Information, Figure S63).
3-(Thiophen-2-ylmethoxy)aspartate (13h). Light-yellow solid, 40
mg (conversion 98%, isolated yield 48%). 1H NMR (500 MHz,
D2O): δ 7.46 (dd, J = 5.0, 1.3 Hz, 1H), 7.11 (dd, J = 3.4, 1.1 Hz, 1H),
7.04 (dd, J = 5.0, 3.4 Hz, 1H), 4.88 (d, J = 12.6 Hz, 1H), 4.69 (d, J =
12.6 Hz, 1H), 4.35 (d, J = 2.3 Hz, 1H), 3.99 (d, J = 2.3 Hz, 1H). 13C
NMR (126 MHz, D2O): δ 175.5, 171.3, 139.0, 128.2, 127.3, 127.0,
76.5, 66.3, 56.4. HRMS: calcd for C9H12NO5 [M + H]
+ 246.0431,
found 246.0430. HPLC: purity 98%, retention time 5.1 min.
3-(Furan-3-ylmethoxy)aspartate (13i). Light-yellow solid, 21 mg
(conversion 98%, isolated yield 35%). 1H NMR (500 MHz, D2O): δ
7.54−7.53 (m, 1H), 7.49 (t, J = 1.7 Hz, 1H), 6.51−6.48 (m, 1H),
4.59 (d, J = 12.1 Hz, 1H), 4.40 (d, J = 12.1 Hz, 1H), 4.31 (d, J = 2.3
Hz, 1H), 3.98 (d, J = 2.3 Hz, 1H). 13C NMR (126 MHz, D2O): δ
175.8, 171.4, 143.8, 141.9, 120.8, 110.5, 76.6, 63.4, 56.5. HRMS: calcd
for C9H12NO6 [M + H]
+ 230.0659, found 230.0659. HPLC: purity
96%, retention time 4.4 min.
3-(Furan-2-ylmethoxy)aspartate (13j). Light-yellow solid 26 mg
(conversion 98%, isolated yield 39%). 1H NMR (500 MHz, D2O): δ
7.51 (dd, J = 1.9, 0.9 Hz, 1H), 6.47 (d, J = 3.2 Hz, 1H), 6.42 (dd, J =
3.2, 1.9 Hz, 1H), 4.62 (d, J = 13.2 Hz, 1H), 4.50 (d, J = 13.2 Hz, 1H),
4.32 (d, J = 2.4 Hz, 1H), 3.97 (d, J = 2.4 Hz, 1H). 13C NMR (126
MHz, D2O): δ 175.4, 171.3, 150.1, 143.8, 111.0, 110.4, 76.6, 63.9,
56.4. HRMS: calcd for C9H12NO6 [M + H]
+ 230.0659, found
230.0659. HPLC: purity 98%, retention time 4.4 min.
(L-threo)-3-(Prop-2-yn-1-yloxy)aspartate (13k). White solid, 5 mg
(conversion 83%, isolated yield 47%). 1H NMR (500 MHz, D2O): δ
4.49 (d, J = 2.3 Hz, 1H), 4.30 (dd, J = 16.0, 2.4 Hz, 1H), 4.20 (dd, J =
16.0, 2.4 Hz, 1H), 4.02 (d, J = 2.3 Hz, 1H), 2.83 (t, J = 2.4 Hz, 1H).
13C NMR (126 MHz, D2O): δ 175.3, 171.4, 76.8, 76.3, 76.3, 57.7,
56.5. HRMS: calcd for C7H10NO5 [M + H]
+ 188.0554, found
188.0550. HPLC: purity 97%, retention time 2.0 min. Comparison of
the 1H NMR data of 13k with the 1H NMR data of chemically
prepared racemic (DL-threo)-19c and (DL-erythro)-19c showed that
the de of product 13k was >98% (Supporting Information, Figure S3).
Chiral HPLC analysis: Crownpak CR-I (+) 150 mm × 3 mm. Phase
A, ACN + 0.5% TFA; phase B, H2O + 0.5% TFA, A/B = 98:2. Flow
rate 0.4 mL/min, column temperature 25 °C, detected by ELSD at 35
°C, tR = 3.2 min, ee > 99% (Supporting Information, Figure S64).
Synthesis of (DL-threo)- and (DL-erythro)-3-Substituted Asp
Derivatives. (DL-threo)-Dimethyl 2-[(tert-Butoxycarbonyl)amino]-
3-hydroxy Succinate (17). The chemical synthesis of compound (DL-
threo)-16 has been described elsewhere.23 To a stirred solution of 16
(622 mg, 2 mmol) in THF/MeOH (1:1, 30 mL) was added Pd/C
10% (50.0 mg) under nitrogen atmosphere. The reaction was stirred
under H2 atmosphere (balloon) for 2 h at room temperature. After
completion of the reaction, the reaction mixture was ﬁltered through
Celite and washed with MeOH (5 mL). The ﬁltrate was concentrated
under vacuum to provide a colorless oil which was directly used for
the next step without puriﬁcation. To a stirred solution of the
colorless oil in dry DCM (20 mL) was added TEA (300 mg, 3 mmol)
and Boc2O (654 mg, 3 mmol) under cooling in an ice-bath. After 10
min, the cooling was removed and the reaction mixture was stirred at
room temperature for further 24 h. After completion of the reaction,
the reaction mixture was diluted with DCM (20 mL) and washed with
0.5 M HCl (50 mL), saturated NaHCO3 solution (50 mL), and brine
(50 mL). The organic layer was dried over Na2SO4 and concentrated
under vacuum to give crude product 17, which was puriﬁed via ﬂash
chromatography (EtOAc/petroleum ether, 15%, v/v) to provide pure
17 as a white solid (460 mg, two-step yield 83%). 1H NMR (500
MHz, CDCl3): δ 5.29 (d, J = 9.0 Hz, 1H), 4.78 (d, J = 9.3 Hz, 1H),
4.69 (dd, J = 5.7, 2.0 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.24 (d, J =
5.5 Hz, 1H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 172.4,
170.0, 155.4, 80.4, 71.2, 56.2, 53.2, 53.0, 28.2 (3C). HRMS: calcd for
C11H19NO7Na [M + Na]
+ 300.1054, found 300.1052.
Dimethyl 2-(Cyclopropylmethoxy)-3-[(tert-butoxycarbonyl)-
amino]succinate (18a). To a stirred solution of compound 17
(195 mg, 0.70 mmol) in dry DMF (3 mL) was added
bromomethylcyclopropane (191 mg, 1.4 mmol) at −20 °C. After
10 min, NaH (60% in mineral oil, 28 mg, 0.70 mmol) was added to
the reaction mixture. The reaction mixture was stirred at −20 °C for 4
h and stirred at 4 °C for further 8 h. After completion of the reaction,
the reaction mixture was quenched with cold water, extracted with
EtOAc (30 mL × 3), washed with brine (50 mL × 3), and dried over
Na2SO4. The solvent was evaporated to provide crude product, which
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was puriﬁed via ﬂash chromatography (EtOAc/petroleum ether, 10%,
v/v) to give pure (DL-threo)-18a (26 mg, 11%) and (DL-erythro)-18a
(9 mg, 4%) as clear oil.
(DL-threo)-18a. 1H NMR (500 MHz, CDCl3): δ 5.33 (d, J = 9.9
Hz, 1H), 4.80 (dd, J = 10.0, 2.4 Hz, 1H), 4.53 (d, J = 2.1 Hz, 1H),
3.77 (s, 3H), 3.74 (s, 3H), 3.50 (dd, J = 10.6, 6.9 Hz, 1H), 3.21 (dd, J
= 10.5, 7.0 Hz, 1H), 1.41 (s, 9H), 1.02−0.95 (m, 1H), 0.54−0.46 (m,
2H), 0.19−0.11 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 170.1,
170.0, 155.6, 80.3, 77.6, 76.0, 56.2, 52.8, 52.5, 28.3 (3C), 10.2, 3.4,
2.7. HRMS: calcd for C15H25NO7Na [M + Na]
+ 354.1523, found
354.1522.
(DL-erythro)-18a. 1H NMR (500 MHz, CDCl3): δ 5.43 (d, J = 8.9
Hz, 1H), 4.85 (dd, J = 8.9, 3.4 Hz, 1H), 4.35 (d, J = 3.4 Hz, 1H), 3.77
(s, 3H), 3.73 (s, 3H), 3.56 (dd, J = 10.7, 6.9 Hz, 1H), 3.34 (dd, J =
10.7, 7.0 Hz, 1H), 1.45 (s, 9H), 1.06−1.00 (m, 1H), 0.56−0.49 (m,
2H), 0.24−0.17 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 170.1,
169.5, 155.3, 80.4, 78.3, 76.2, 55.7, 52.8, 52.4, 28.4 (3C), 10.2, 3.5,
2.7. HRMS: calcd for C15H25NO7Na [M + Na]
+ 354.1523, found
354.1523.
Dimethyl 2-(Thiophen-3-ylmethoxy)-3-[(tert-butoxycarbonyl)-
amino]succinate (18b). To a stirred solution of compound 17
(197 mg, 0.71 mmol) in dry DMF (3 mL) was added 3-
(bromomethyl)thiophene (251 mg, 1.42 mmol) at −20 °C. After
10 min, NaH (60% in mineral oil, 28.4 mg, 0.71 mmol) was added to
the reaction mixture. The reaction mixture was stirred at −20 °C for 4
h and stirred at 4 °C for further 8 h. After completion of the reaction,
the reaction mixture was quenched with cold water, extracted with
EtOAc (30 mL × 3), washed with brine (50 mL × 3), and dried over
Na2SO4. The solvent was evaporated to provide crude product, which
was puriﬁed via ﬂash chromatography (EtOAc/petroleum ether, 10%,
v/v) to give (DL-threo)-18b (140 mg, 53%) and (DL-erythro)-18b (27
mg, 10%) as clear oil.
(DL-threo)-18b. 1H NMR (500 MHz, CDCl3): δ 7.30 (dd, J = 5.0,
2.9 Hz, 1H), 7.18 (dd, J = 3.0, 1.1 Hz, 1H), 6.98 (dd, J = 4.9, 1.3 Hz,
1H), 5.34 (d, J = 10.0 Hz, 1H), 4.82−4.77 (m, 2H), 4.47 (d, J = 2.3
Hz, 1H), 4.43 (d, J = 12.3 Hz, 1H), 3.77 (s, 3H), 3.65 (s, 3H), 1.42
(s, 9H). 13C NMR (126 MHz, CDCl3): δ 169.9, 169.8, 155.6, 137.7,
127.7, 126.4, 124.2, 80.4, 76.6, 67.8, 56.1, 52.8, 52.6, 28.3 (3C).
HRMS: calcd for C16H24NO7S [M + H]
+ 374.1268, found 374.1267.
(DL-erythro)-18b. 1H NMR (500 MHz, CDCl3): δ 7.30 (dd, J =
4.9, 2.9 Hz, 1H), 7.22 (d, J = 2.8 Hz, 1H), 7.07 (dd, J = 5.0, 1.2 Hz,
1H), 5.33 (d, J = 8.7 Hz, 1H), 4.87 (dd, J = 8.6, 3.0 Hz, 1H), 4.84 (d,
J = 12.3 Hz, 1H), 4.57 (d, J = 12.3 Hz, 1H), 4.27 (d, J = 3.1 Hz, 1H),
3.79 (s, 3H), 3.73 (s, 3H), 1.43 (s, 9H). 13C NMR (126 MHz,
CDCl3): δ 169.7, 169.2, 155.0, 137.8, 127.3, 126.3, 123.8, 80.3, 77.4,
68.2, 55.6, 52.7, 52.3, 28.3 (3C). HRMS: calcd for C16H24NO7S [M +
H]+ 374.1268, found 374.1266.
Dimethyl 2-(Prop-2-yn-1-yloxy)-3-[(tert-butoxycarbonyl)amino]-
succinate (18c). To a stirred solution of compound 17 (200 mg, 0.72
mmol) in dry DMF (3 mL) was added propargyl bromide (80% in
toluene, 156 μL, 1.44 mmol) at −20 °C. After 10 min, NaH (60% in
mineral oil, 29 mg, 0.72 mmol) was added to the reaction mixture.
The reaction mixture was stirred at −20 °C for 4 h and stirred at 4 °C
for further 8 h. After completion of the reaction, the reaction mixture
was quenched with cold water, extracted with EtOAc (30 mL × 3),
washed with brine (50 mL × 3), and dried over Na2SO4. The solvent
was evaporated to provide crude product, which was puriﬁed via ﬂash
chromatography (EtOAc/petroleum ether, 10%, v/v) to give (DL-
threo)-18c (54 mg, 24%) and (DL-erythro)-18c (25 mg, 11%) as clear
oil.
(DL-threo)-18c. 1H NMR (500 MHz, CDCl3): δ 5.29 (d, J = 9.8
Hz, 1H), 4.87 (dd, J = 9.9, 2.4 Hz, 1H), 4.78 (d, J = 2.3 Hz, 1H), 4.37
(dd, J = 16.3, 2.4 Hz, 1H), 4.20 (dd, J = 16.2, 2.4 Hz, 1H), 3.78 (s,
3H), 3.77 (s, 3H), 2.45 (t, J = 2.4 Hz, 1H), 1.41 (s, 9H). 13C NMR
(126 MHz, CDCl3): δ 169.7, 169.4, 155.5, 80.4, 78.1, 76.0, 75.8, 57.9,
56.0, 52.9, 52.7, 28.3 (3C). HRMS: calcd for C14H21NO7Na [M +
Na]+ 338.1210, found 338.1211.
(DL-erythro)-18c. 1H NMR (500 MHz, CDCl3): δ 5.44 (d, J = 8.7
Hz, 1H), 4.92 (dd, J = 8.7, 2.9 Hz, 1H), 4.58 (d, J = 2.9 Hz, 1H), 4.43
(dd, J = 16.3, 2.4 Hz, 1H), 4.31 (dd, J = 16.3, 2.4 Hz, 1H), 3.79 (s,
3H), 3.72 (s, 3H), 2.45 (t, J = 2.4 Hz, 1H), 1.45 (s, 9H). 13C NMR
(126 MHz, CDCl3): δ 169.4, 169.0, 155.3, 80.4, 78.3, 76.6, 76.2, 58.4,
55.7, 52.9, 52.5, 28.4 (3C). HRMS: calcd for C14H21NO7Na [M +
Na]+ 338.1210, found 338.1211.
(DL-threo)-3-(Cyclopropylmethoxy)aspartate [(DL-threo)-19a]. To
a stirred solution of (DL-threo)-18a (26 mg, 0.08 mmol) in dry DCM
(2 mL) was added triﬂuoroacetic acid (0.8 mL) dropwise under
cooling in an ice-bath. After the complete addition of triﬂuoroacetic
acid, the ice-bath was removed and the reaction was allowed to
proceed at room temperature for further 1.5 h. After completion of
the starting material, the solvent was removed in vacuo to provide
deBoc product quantitatively as a clear oil, which was directly used for
the next step without puriﬁcation.
To a stirred solution of the clear oil in THF/H2O (1:1, each 1 mL)
was added LiOH (9.6 mg, 0.40 mmol), and the reaction mixture was
stirred at room temperature for 2 h. Volatiles were removed in vacuo,
and the residue was washed with EtOAc (1 mL). The aqueous layer
was acidiﬁed with 1 M HCl (until pH = 1) and loaded onto a column
packed with cation-exchange resin (10 g of Dowex 50W X8, 50−100
mesh), which was pretreated with 2 M aqueous ammonia (4 column
volumes), 1 M HCl (2 column volumes), and distilled water (4
column volumes). The column was washed with distilled water (2
column volumes), and the product was eluted with 2 M aqueous
ammonia (2 column volumes). The ninhydrin-positive fractions were
collected and lyophilized to yield the desired product (DL-threo)-19a
as ammonium salt (white solid, 7 mg, two-step yield of 37%). 1H
NMR (500 MHz, D2O): δ 4.40 (d, J = 2.5 Hz, 1H), 4.00 (d, J = 2.5
Hz, 1H), 3.47 (dd, J = 10.7, 7.0 Hz, 1H), 3.30 (dd, J = 10.7, 7.3 Hz,
1H), 1.06−0.98 (m, 1H), 0.57−0.45 (m, 2H), 0.22−0.16 (m, 2H).
13C NMR (126 MHz, D2O): δ 176.0, 171.5, 77.4, 75.8, 56.4, 9.5, 2.7,
2.1. HRMS: calcd for C8H14NO5 [M + H]
+ 204.0866, found
204.0866. HPLC: purity 97%, retention time 4.2 min. Chiral HPLC
analysis: Crownpak CR-I (+) 150 × 3 mm. Phase A, ACN + 0.5%
TFA; phase B, H2O + 0.5% TFA, A/B = 98:2. Flow rate 0.4 mL/min,
column temperature 25 °C, detected by ELSD at 35 °C, tR (D-threo) =
2.3 min, tR (L-threo) = 2.8 min (Supporting Information, Figure S62).
(DL-erythro)-3-(Cyclopropylmethoxy)aspartate [(DL-erythro)-
19a]. Compound (DL-erythro)-19a was prepared from (DL-erythro)-
18a (9 mg, 0.027 mmol) following a procedure similar to that used
for (DL-threo)-19a. The title compound was obtained as a white solid
(3 mg, two-step yield of 46%). 1H NMR (500 MHz, D2O): δ 4.29 (d,
J = 3.8 Hz, 1H), 4.08 (d, J = 3.8 Hz, 1H), 3.50 (dd, J = 10.6, 7.1 Hz,
1H), 3.37 (dd, J = 10.6, 7.3 Hz, 1H), 1.12−1.04 (m, 1H), 0.58−0.51
(m, 2H), 0.27−0.18 (m, 2H). 13C NMR (126 MHz, D2O/DMSO-d6,
1:1): δ 179.8, 179.0, 99.0, 76.5, 60.2, 11.4, 4.5, 3.9. HRMS: calcd for
C8H14NO5 [M + H]
+ 204.0866, found 204.0867.
(DL-threo)-3-(Thiophen-3-ylmethoxy)aspartate [(DL-threo)-19b].
Compound (DL-threo)-19b was prepared from (DL-threo)-18b (140
mg, 0.37 mmol) following a procedure similar to that used for (DL-
threo)-19a. The title compound was obtained as a white solid (40 mg,
two-step yield of 39%). 1H NMR (500 MHz, D2O): δ 7.43 (dd, J =
4.9, 2.9 Hz, 1H), 7.39 (dd, J = 2.9, 1.3 Hz, 1H), 7.12 (dd, J = 4.9, 1.4
Hz, 1H), 4.71 (d, J = 12.1 Hz, 1H), 4.50 (d, J = 11.9 Hz, 1H), 4.30
(d, J = 2.2 Hz, 1H), 3.97 (d, J = 2.3 Hz, 1H). 13C NMR (126 MHz,
D2O): δ 175.8, 171.4, 137.8, 127.8, 126.6, 124.7, 76.9, 67.2, 56.4.
HRMS: calcd for C9H12NO5S [M + H]
+ 246.0431, found 246.0430.
HPLC: purity 98%, retention time 5.2 min. Chiral HPLC conditions:
Nucleosil chiral-1 column with 0.5 mM aqueous CuSO4 solution as
mobile phase with a ﬂow rate of 1.0 mL/min at 60 °C, UV detection
at 254 nm, tR (L-threo) = 7.3 min, tR (D-threo) = 8.3 min (Supporting
Information, Figure S63).
(DL-erythro)-3-(Thiophen-3-ylmethoxy)aspartate [(DL-erythro)-
19b]. Compound (DL-erythro)-19b was prepared from (DL-erythro)-
18b (27 mg, 0.072 mmol) following a procedure similar to that used
for (DL-threo)-19a. The title compound was obtained as a white solid
(7 mg, two-step yield of 35%). 1H NMR (500 MHz, D2O): δ 7.47−
7.45 (m, 2H), 7.19 (dd, J = 4.8, 1.5 Hz, 1H), 4.74 (d, J = 11.9 Hz,
1H), 4.56 (d, J = 11.9 Hz, 1H), 4.16 (d, J = 4.1 Hz, 1H), 3.93 (d, J =
4.1 Hz, 1H). 13C NMR (126 MHz, D2O): δ 175.1, 171.6, 137.8,
127.9, 126.9, 124.9, 78.1, 66.8, 56.6. HRMS: calcd for C9H12NO5S [M
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+ H]+ 246.0431, found 246.0430. HPLC: purity 96%, retention time
4.9 min.
(DL-threo)-3-(Prop-2-yn-1-yloxy)aspartate [(DL-threo)-19c]. Com-
pound (DL-threo)-19c was prepared from (DL-threo)-18c (54 mg, 0.17
mmol) following a procedure similar to that used for (DL-threo)-19a.
The title compound was obtained as a white solid (13 mg, two-step
yield of 34%). 1H NMR (500 MHz, D2O): δ 4.50 (d, J = 2.4 Hz, 1H),
4.31 (dd, J = 16.0, 2.5 Hz, 1H), 4.21 (dd, J = 16.0, 2.4 Hz, 1H), 4.03
(d, J = 2.4 Hz, 1H), 2.85 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz,
D2O): δ 175.3, 171.4, 78.6, 76.9, 76.4, 57.7, 56.5. HRMS: calcd for
C7H10NO5 [M + H]
+ 188.0554, found 188.0554. HPLC: purity 95%,
retention time 2.0 min. Chiral HPLC analysis: Crownpak CR-I (+)
150 mm × 3 mm. Phase A, ACN + 0.5%TFA; phase B, H2O + 0.5%
TFA, A/B = 98:2. Flow rate 0.4 mL/min, column temperature 25 °C,
detected by ELSD at 35 °C, tR (D-threo) = 2.4 min, tR (L-threo) = 3.0
min (Supporting Information, Figure S64).
(DL-erythro)-3-(Prop-2-yn-1-yloxy)aspartate [(DL-erythro)-19c].
Compound (DL-erythro)-19c was prepared from (DL-erythro)-18c
(25 mg, 0.08 mmol) following a procedure similar to that used for
(DL-threo)-19a. The title compound was obtained as a white solid (6
mg, two-step yield of 34%). 1H NMR (500 MHz, D2O): δ 4.37 (dd, J
= 16.1, 2.2 Hz, 1H), 4.31 (d, J = 3.8 Hz, 1H), 4.22 (dd, J = 16.1, 2.1
Hz, 1H), 4.01 (d, J = 3.8 Hz, 1H), 2.87 (t, J = 2.4 Hz, 1H). 13C NMR
(126 MHz, D2O): δ 174.7, 171.7, 78.2, 78.1 (2C), 57.4, 56.5. HRMS:
calcd for C7H10NO5 [M + H]
+ 188.0554, found 188.0553.
Synthesis of Precursors for Hybrid Compounds. (L-threo)-1-
(tert-Butyl)-4-methyl-2-amino-3-(benzyloxy)succinate (21). The
multigram scale synthesis of L-TBOA (2) was based on a previously
published procedure.24 To a stirred suspension of 2 (1.20 g, 5 mmol)
in dry MeOH (20 mL) was added SOCl2 (0.45 mL, 5 mmol)
dropwise (in an ice-bath). After 20 min, the cooling system was
removed and the reaction mixture was stirred for further 16 h. After
completion of the reaction, the solvent was removed to provide crude
product 20 as a white solid (1.4 g, 96%). No puriﬁcation was needed
and the crude product 20 was directly used for the next step. To a
stirred suspension of compound 20 (1.3 g, 4.5 mmol) in t-BuOAc (20
mL) was added BF3/Et2O (3 mL). The reaction mixture was stirred at
room temperature for 16 h. After completion of the reaction, 2 M
NaOH (20 mL) was added to the reaction mixture and stirred for
another 10 min. The reaction mixture was extracted with EtOAc (30
mL × 3), washed with brine (50 mL × 3), and dried over Na2SO4.
The organic solvent was evaporated to provide pure product 21 as a
clear oil (1.25 g, 91%). 1H NMR (500 MHz, CDCl3): δ 7.36−7.28
(m, 5H), 4.82 (d, J = 11.3 Hz, 1H), 4.48 (d, J = 3.1 Hz, 1H), 4.45 (d,
J = 11.3 Hz, 1H), 3.83 (s, 3H), 3.80 (d, J = 3.1 Hz, 1H), 1.76 (brs,
2H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 171.7, 171.0,
137.1, 128.4 (2C), 128.2 (2C), 128.0, 81.9, 79.3, 73.3, 57.9, 52.2, 28.0
(3C). HRMS: calcd for C16H24NO5 [M + H]
+ 310.1649, found
310.1651.
(L-threo)-2-(Benzyloxy)-4-(tert-butoxy)-3-[(tert-butoxycarbonyl)-
amino]-4-oxobutanoic Acid (23). To a stirred solution of 21 (1.2 g,
3.9 mmol) in dry DCM (25 mL) was added DIEA (1.3 mL, 8 mmol)
and Boc2O (1.7 g, 7.8 mmol) under cooling in an ice-bath. After 10
min, the cooling system was removed and the reaction mixture was
stirred at room temperature for further 24 h. After completion of the
reaction, the reaction mixture was diluted with DCM (20 mL), and
washed with 0.5 M HCl (50 mL), saturated NaHCO3 solution (50
mL), and brine (50 mL). The organic layer was dried over Na2SO4
(s) and concentrated under vacuum to give product 22 as a clear oil
(1.35 g, 85%). No puriﬁcation was needed and compound 22 was
directly used for the next step. To a stirred solution of 22 (1.35 g, 3.3
mmol) in THF/H2O (1:1, each 5 mL) was added LiOH (240 mg, 10
mmol) under cooling in an ice-bath. After 10 min, the cooling system
was removed and the reaction mixture was stirred at room
temperature for further 8 h. After completion of the starting material,
THF was removed in vacuo and the resulting aqueous solution was
acidiﬁed with 1 M HCl to pH = 1. The reaction mixture was extracted
with EtOAc (50 mL × 3), washed with brine (50 mL × 3), and dried
over Na2SO4. The organic solvent was evaporated to provide crude
product, which was puriﬁed via ﬂash chromatography (MeOH/DCM
10%, v/v) to give 23 as a clear oil (640 mg, 49%). 1H NMR (500
MHz, DMSO-d6): δ 13.10 (brs, 1H), 7.36−7.29 (m, 5H), 6.45 (d, J =
9.6 Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.46−4.37 (m, 3H), 1.37 (s,
9H), 1.35 (s, 9H). 13C NMR (126 MHz, DMSO-d6): δ 170.6, 168.3,
155.4, 137.5, 128.1 (2C), 127.7 (2C), 127.6, 81.5, 78.7, 77.4, 72.0,
56.2, 28.1 (3C), 27.5 (3C). HRMS: calcd for C20H30NO7 [M + H]
+
396.2017, found 396.2011.
(L-threo)-tert-Butyl-3-(benzyloxy)-4-[[4-(2-bromo-4,5-
diﬂuorophenoxy)phenyl]amino]-2-[(tert-butoxycarbonyl)amino]-
4-oxobutanoate (26). To a stirred solution of 23 (150 mg, 0.38
mmol) in dry DCM (3 mL) was added EDCI (96 mg, 0.5 mmol),
HOBT (67 mg, 0.5 mmol), and TEA (50 mg, 0.5 mmol) under
cooling in an ice-bath. After 30 min, the cooling system was removed
and a solution of amine 24 (100 mg, 0.33 mmol) in DCM (1 mL) was
added to the reaction mixture. The reaction mixture was stirred for 12
h at room temperature. After completion of the reaction, the solvent
was removed in vacuo. The reaction mixture was extracted with
EtOAc (20 mL × 3), washed with brine (50 mL), and dried over
Na2SO4. The organic solvent was evaporated to provide crude
product, which was puriﬁed via ﬂash chromatography (EtOAc/
petroleum ether 5%, v/v) to give 26 as a white solid (70 mg, 27%). 1H
NMR (500 MHz, CDCl3): δ 8.19 (s, 1H), 7.50−7.46 (m, 3H), 7.41−
7.35 (m, 5H), 6.93 (dd, J = 9.0, 3.2 Hz, 2H), 6.73−6.70 (m, 1H), 5.34
(d, J = 9.4 Hz, 1H), 4.83 (d, J = 9.4 Hz, 1H), 4.72 (d, J = 11.2 Hz,
1H), 4.62 (dd, J = 11.3, 3.2 Hz, 1H), 4.51 (s, 1H), 1.48 (s, 9H), 1.33
(s, 9H). 13C NMR (126 MHz, CDCl3): δ 168.9, 167.4, 155.3, 152.7,
149.1 (dd, J = 409.5 Hz, 13.9 Hz), 150.5 (dd, J = 7.6, 3.8 Hz), 147.0
(dd, J = 408.2 Hz, 13.9 Hz), 136.2, 133.5, 129.0 (2C), 128.8, 128.5
(2C), 121.8, 121.7, 121.6, 119.2, 115.6 (d, J = 22.7 Hz), 108.7 (d, J =
21.4 Hz), 107.8 (dd, J = 6.3 Hz, 3.8 Hz), 83.0, 80.8, 80.2, 74.4, 56.0,
28.2 (3C), 28.1 (3C). HRMS: calcd for C32H36BrF2N2O7 [M + H]
+
677.1668, found 677.1675.
(L-threo)-tert-Butyl-4-[(9H-ﬂuoren-2-yl)amino]-3-(benzyloxy)-2-
[(tert-butoxycarbonyl) amino]-4-oxobutanoate (27). Compound
27 was prepared from 23 (100 mg, 0.25 mmol) and (9H)-ﬂuoren-2-
amine (25, 58 mg, 0.32 mmol), using EDCI (61 mg, 0.32 mmol),
HOBT (43 mg, 0.32 mmol), and TEA (32 mg, 0.32 mmol) and
following a procedure similar to that used for 26. The title product
was obtained as a white solid (128 mg, 90%). 1H NMR (500 MHz,
CDCl3): δ 8.36 (s, 1H), 7.95 (s, 1H), 7.73 (dd, J = 17.7, 7.9 Hz, 2H),
7.55 (d, J = 7.5 Hz, 1H), 7.46−7.37 (m, 6H), 7.34−7.29 (m, 2H),
5.43 (d, J = 9.5 Hz, 1H), 4.91 (dd, J = 9.4, 2.3 Hz, 1H), 4.77 (d, J =
11.1 Hz, 1H), 4.69 (d, J = 11.0 Hz, 1H), 4.57 (d, J = 2.3 Hz, 1H),
3.90 (s, 2H), 1.52 (s, 9H), 1.35 (s, 9H). 13C NMR (126 MHz,
CDCl3): δ 169.0, 167.3, 155.3, 144.4, 143.3, 141.3, 138.4, 136.3,
135.8, 129.0 (2C), 128.8, 128.5 (2C), 126.8, 126.5, 125.1, 120.1,
119.6, 118.6, 116.9, 83.0, 80.9, 80.2, 74.3, 56.0, 37.1, 28.2 (3C), 28.1
(3C). HRMS: calcd for C33H39N2O6 [M + H]
+ 559.2803, found
559.2808.
Cell Culture. All cell lines were cultured at 37 °C in a humidiﬁed
5% CO2 atmosphere. The hEAAT1-, hEAAT2-, and hEAAT3-
HEK293 cell lines were maintained in Culture Medium I [Dulbecco’s
Modiﬁed Eagle Medium Glutamax-I (DMEM) supplemented with
5% dialyzed fetal bovine serum, 100 U/mL penicillin, 100 μg/mL
streptomycin, and 1 mg/mL G-418], and the stable rEAAT4-tsA201
cell line was maintained in Culture Medium II (DMEM supplemented
with 5% tetracycline-free fetal bovine serum, 100 U/mL penicillin,
100 μg/mL streptomycin, 0.2 mg/mL hygromycin B, and 10 μg/mL
blasticidin).
[3H]-D-Asp Uptake Assay. The pharmacological characterization
of various reference EAAT ligands and test compounds in the [3H]-D-
Asp uptake assay was performed essentially as described previously.25
The day before the assay, cells were split into poly-D-lysine-coated
white 96-well plates (PerkinElmer, Boston, MA) in Culture Medium I
(hEAAT1-, hEAAT2-, and hEAAT3-HEK293) or in Culture Medium
II supplemented with 1 μg/mL tetracycline (rEAAT4-tsA201). After
16−24 h, the culture medium was aspirated and cells were washed
twice with 100 μL of assay buﬀer (Hank’s Buﬀered Saline Solution
supplemented with 20 mM HEPES, 1 mM CaCl2, and 1 mM MgCl2,
pH 7.4). Then 50 μL of assay buﬀer supplemented with 100 nM
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[3H]-D-Asp (PerkinElmer, Boston, MA) and various concentrations of
test compounds were added to the wells, and the plate was incubated
at 37 °C for 4 min. Notably, aspartate uptake is still in the linear range
at 4 min after initiation of uptake (for all four cell lines). Nonspeciﬁc
[3H]-D-Asp uptake/binding in the cells was determined in the
presence of 3 mM L-Glu. The assay mixtures were quickly removed
from the wells, and the cells were washed with 3 × 100 μL ice-cold
assay buﬀer, after which 150 μL of Microscint-20 scintillation ﬂuid
(PerkinElmer, Boston, MA) was added to each well. Then the plate
was shaken for at least 1 h and counted in a TopCounter
(PerkinElmer, Boston, MA). For each compound, three or four
independent assays were performed in duplicate (the speciﬁc numbers
are stated for each compound at the four diﬀerent transporters in
Table 2).
The FLIPR Membrane Potential Blue (FMP) Assay. The
substrate or nonsubstrate inhibitor properties of all 3-substituted Asp
derivatives were tested at hEAAT1-, hEAAT2-, and hEAAT3-HEK293
cells in the FMP assay essentially as previously described, using L-Glu
and L-THA as reference substrates and DL-TBOA as a reference
nonsubstrate inhibitor at the EAATs.25 Brieﬂy, the cells were split into
poly-D-lysine-coated black 96-well plates (BD Biosciences, Palo Alto,
CA) with a clear bottom. The following day, the culture medium was
aspirated, and the cells were washed once with 100 μL assay buﬀer
(140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 11 mM
HEPES, 10 mM D-glucose, pH 7.4), after which the cells were
incubated in 100 μL of assay buﬀer supplemented with FMP dye (0.5
mg/mL) at 37 °C for 30 min. In the inhibitor experiments, the test
compound (300 μM) was added to the assay buﬀer at this point. The
96-well plate was assayed in a FLEXStation benchtop multimode
microplate reader (Molecular Devices) measuring emission [in
ﬂuorescence units (FU)] at 565 nm caused by excitation at 525 nm
before and up to 90 s after addition of 33.3 μL of assay buﬀer
supplemented with test compound in the substrate experiments
(giving rise to an assay concentration of 300 μM of the test
compound) or with L-Glu in the inhibitor experiments (giving rise to
an assay concentration of L-Glu EC80 for the speciﬁc EAAT). For each
compound, three independent experiments were done in triplicate.
Data Analysis. Data from the [3H]-D-Asp uptake assay were ﬁtted
to the equation %Uptake = 100%Uptake/[1 + ([L]/IC50)
nH], and
IC50 values for the test compounds were derived from this equation.
Concentration−inhibition curves were generated by nonweighted
least-squares ﬁts using the program KaleidaGraph 3.08 (Synergy
Software, Reading, PA).
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